In patients with GN or vasculitis, ANCAs are directed against proteinase 3 (PR3) or
myeloperoxidase (MPO). The differences between PR3-ANCA-associated vasculitis (AAV) …

ANCA-associated-vasculitis (AAV) comprises three different diseases entities: Churg–
Strauss syndrome, microscopic polyangiitis, and Wegener's granulomatosis. AAV is an …

Alternative C activation is involved in the pathogenesis of ANCA-associated vasculitis.
However, glucocorticoids used as treatment contribute to the morbidity and mortality of …

Eleana Ntatsaki1, 2, David Carruthers3, Kuntal Chakravarty4, David D'Cruz5, Lorraine
Harper6, David Jayne7, Raashid Luqmani8, John Mills9, Janice Mooney10, Michael …

Objective Rituximab is effective induction therapy in refractory or relapsing antineutrophil
cytoplasmic antibody–associated vasculitis (AAV). However, further relapse is common, and …

Objective. ANCA-associated vasculitis (AAV) is characterized by a chronic relapsing course.
Rituximab (RTX) is an effective maintenance treatment; however, the long-term outcomes …

Background Rituximab is a B cell depleting anti-CD20 monoclonal antibody. CD20 is not
expressed on mature plasma cells and accordingly rituximab does not have immediate …

Objectives. To perform a literature review and develop recommendations for the use of
rituximab in ANCA-associated vasculitis. Methods. A committee of experts (five …

Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) include Wegener
granulomatosis, microscopic polyangiitis, Churg–Strauss syndrome and renal-limited …

Background: Granulomatosis with polyangiitis (GPA) presents a wide spectrum of
manifestations from the common respiratory symptoms to infrequent neurological and …